Coronary Artery Calcium Scoring: a Valuable Aid in Shared Decision Making Among Non-traditional Risk Markers
AbstractPurpose of the ReviewThe purpose of this study was to evaluate the utility of coronary artery calcium (CAC) scoring and compare it with other non-traditional cardiovascular risk markers for improvement in cardiovascular risk assessment.Recent FindingsCAC scoring refines risk assessment among asymptomatic patients eligible for primary prevention across the spectrum of cardiovascular risk. Its use has been well-validated in several multi-ethnic population-based cohorts. With the recent ACC/AHA cholesterol treatment guidelines expanding the eligibility for statin therapy for primary prevention, the absence of CAC can be a powerful tool for identifying those at lower risk of future cardiovascular events. CAC is superior to other non-traditional risk markers recognized by the current risk assessment guidelines for re-classifying patients to appropriate risk categories and improving discrimination of risk beyond traditional risk factors.SummaryCAC scoring is a reliable decision-making tool for improving cardiovascular risk assessment and performs better than other non-traditional risk markers, particularly when used to identify those at lower risk (i.e., CAC = 0).
Publication date: October 2019Source: Canadian Journal of Diabetes, Volume 43, Issue 7, SupplementAuthor(s): Sonia Butalia, Rachelle Lee, Kerry Mcbrien, Alexander Leung, Todd Anderson, Chris Naugler, Hude Quan, Guanmin Chen, Minghan Lu, David Campbell
Publication date: October 2019Source: Canadian Journal of Diabetes, Volume 43, Issue 7, SupplementAuthor(s): David Campbell, Rachelle Lee, Kerry Mcbrien, Alexander Leung, Todd Anderson, Chris Naugler, Hude Quan, Guanmin Chen, Minghan Lu, Sonia Butalia
WEDNESDAY, Sept. 18, 2019 -- Could popping just one pill a day keep your heart and blood vessels humming along for years to come? Possibly. Researchers just tested a combo pill containing low doses of two blood pressure medications, a statin and a...
Publication date: Available online 18 September 2019Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Shih-Wei Lai, Yu-Hung Kuo, Chia-Wei Fang, Kuan-Fu Liao
ConclusionBesides markedly lowering LDL-c levels, our results suggest that HC patients benefit from PCSK9 mAb treatment also for reducing platelet reactivity and increasing platelet sensitivity to the inhibitory effects of aspirin. These effects on platelets could play a role in the reduction of CV event incidence in patients treated with PCSK9-inhibitors.
Dr Aseem Malhotra claimed millions of Britons had been forced to unnecessarily suffer a host of side effects at the hands of the pills. It's thought around 6million patients are taking statins.
AbstractBackgroundIt is well researched that individuals in long-term care (LTC) are prescribed a greater number of medications, the leading risk factor for inappropriate prescribing, and are thus at greater risk of adverse drug reactions as a result. Many tools with explicit criteria are described in the literature for assessing potentially inappropriate prescribing (PIP) in the general geriatric population, but few have been developed to examine prescribing in LTC.MethodsThis was a point prevalence observational study of patients aged>65 years residing in three HSE-run LTC facilities in Cork. Demographic characteristi...
ConclusionThe prognostic value of Fibrinogen after stroke or TIA remains unclear. Standardised methods and fully-adjusted multivariable analysis are needed in future prognostic studies.
A decade ago, statin persistence was